Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

US-based cancer therapy developer Pyxis Oncology secured $168m in an upsized initial public offering on Friday representing exits for pharmaceutical firms Bayer, Pfizer and Ipsen. The company issued 10.5 million shares on the Nasdaq Global Select Market priced at the top of its $14 to $16 range. They opened at $18.88 but crashed to $13.20…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.